Market Newsdesk

AIRPORT CITY, Israel, March 10, 2025 /PRNewswire/ — MySize, Inc. (NASDAQ: MYSZ) (“MySize” or the “Company”), an omnichannel e-commerce platform and provider of AI-driven measurement solutions, today announced the appointment of Roy Golan to its Board of Directors. Mr. Golan will serve as a Director on the Board, leveraging his extensive experience in initial public offerings (IPOs), fundraising, and mergers and acquisitions (M&As) to support MySize’s strategic growth objectives.

Roy Golan brings over two decades of financial leadership and corporate finance expertise to MySize. Throughout his career, he has held senior executive roles where he successfully guided companies through IPO processes, secured significant capital for expansion, and executed strategic M&A transactions. This proven track record of driving growth and value creation will be instrumental as MySize continues to expand its business and explore new opportunities.

Mr. Golan’s appointment comes at a pivotal time for MySize, which is focused on accelerating growth and enhancing its market position. The Company believes that adding an experienced financial expert to the Board will not only bolster its strategic execution but also reinforce investor confidence in MySize’s direction.

“We are thrilled to welcome Roy to our Board of Directors,” said Ronen Luzon, CEO and Founder of MySize, Inc. “Roy’s extensive experience in corporate finance and strategic transactions will be invaluable as we execute our growth strategy. His guidance in matters of financial governance and his track record of driving shareholder value align perfectly with our mission to scale the business and deliver long-term value to our investors.”

“I am honored to join the Board of MySize at such an exciting time,” said Roy Golan. “MySize has a strong vision and innovative technology that position it for growth. I look forward to working with my fellow board members and the management team, leveraging my experience in capital markets and M&As to help the Company achieve its goals and enhance value for shareholders.”

About MySize, Inc.

MySize, Inc. (Nasdaq: MYSZ) is an omnichannel e-commerce platform and provider of AI-driven measurement solutions. The Company’s proprietary measurement technology, combined with products like MySizeID and the recently acquired Naiz Fit, helps retailers drive revenue growth and reduce costs by improving fit accuracy and reducing returns. MySize also operates Orgad, an online retailer platform with expertise in e-commerce, supply chain management, and technology, functioning as a third-party seller on Amazon and other online marketplaces. In addition, MySize has launched innovative retail tools such as the FirstLook Smart Mirror, a mirror-like touch display that enhances in-store shopping experiences and provides contactless checkout. MySize’s technology has broad applications across the apparel, e-commerce, DIY, shipping, and parcel delivery industries. Headquartered in Airport City, Israel, MySize is dedicated to delivering cutting-edge solutions that improve retailers’ profitability and shopper satisfaction. For more information, please visit www.mysizeid.com.

Forward-Looking Statements:

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to its strategic and business plans, technology, relationships, objectives, and expectations for its business, growth. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results may differ materially from those in the forward-looking statements and the trading price for our common stock may fluctuate significantly. Forward-looking statements also are affected by the risk factors described in the Company’s filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

For more information or to schedule a demonstration, please contact:

Or Kles, CFO
Email: [email protected] 

Logo: https://mma.prnewswire.com/media/689689/3320229/MySize_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/mysize-inc-appoints-roy-golan-to-board-of-directors-302396918.html

SOURCE My Size Inc.

Shift4 has made a capital investment in Lunchbox, selecting the technology solution provider as the enterprise partner for its SkyTab POS solution. The news comes alongside Lunchbox’s appointment of James Walker as its new CEO.

NEW YORK
, March 10, 2025 /PRNewswire/ — Lunchbox, the leader in enterprise restaurant catering and off-premise technology, has announced the appointment of James Walker as CEO as the company enters a new era of growth with a clear roadmap to profitability and innovation. With record momentum—including high-profile enterprise brands joining its expanding portfolio, an explosive rise in product adoption, and a sharpened focus on the next generation of restaurant technology—Lunchbox has also announced a funding round led by a strategic investment from Shift4, the leader in integrated payments and commerce technology.

James Walker Appointed as CEO, Nabeel Alamgir Executive Chairman

James Walker and Nabeel Alamgir will work as strategic partners to drive Lunchbox into its next phase of growth. Walker will lead growth and execution, leveraging decades of industry experience, while Alamgir doubles down on AI and automation, ensuring that Lunchbox remains the industry’s most advanced, operator-first platform. Together, they’re building a Lunchbox that helps operators scale faster, work smarter, and stay ahead leveraging best-in-class technology.

“We’re charting a bold new course for restaurant technology,” said Nabeel Alamgir, Executive Chairman of Lunchbox. “With James at the helm, Shift4’s backing, and our relentless focus on innovation, we’re not just building for today—we’re designing for tomorrow’s restaurant operators.”

James Walker Brings Operator Edge, Decades of Experience 
A seasoned industry leader, Walker brings 30+ years of executive experience across QSR, Fast Casual, and Casual Dining, scaling global brands like Subway®, Nathan’s Famous®, and Cinnabon®. Before stepping into the CEO role, he has served on Lunchbox’s Board of Directors for over x years, playing a key role in securing its investment and partnership with Shift4.

Walker, widely respected in restaurant tech and delivery, combines expertise in enterprise growth, AI strategy, and operations to drive Lunchbox’s next phase of growth. He holds an MBA from Duke and has completed executive programs at Harvard, Yale, and MIT, including a focus on AI strategy at MIT.

“Lunchbox is a pioneer in restaurant innovation, and I’m honored to lead the charge alongside Nabeel Alamgir,” said James Walker, CEO of Lunchbox. “Restaurants deserve technology that works for them, not against them. My focus is on scaling our solutions to meet the evolving needs of enterprise brands, ensuring they have the tools to compete and succeed in today’s digital-first landscape.”

Record Growth and a Focus on the Future
Lunchbox has experienced record-breaking growth, with a 340% increase in average deal size since 2022, as it continues moving upmarket with brands like Paris Baguette, Pei Wei, Friendly’s, Hawaiian Bros, Biscuitville, and Papa John’s. The company’s long-standing partners—including Clean Juice and other multi-unit brands—have contributed to 300% growth in product adoption, with the average number of products per client rising from 1 to 4 since 2022.

Strategic Investment Led by Shift4
Fueling this momentum, Lunchbox has secured a new round of funding, led by Shift4, further validating its market leadership and profitability strategy. This funding will accelerate product development, enhance enterprise capabilities, and reinforce Lunchbox’s commitment to helping restaurant brands scale seamlessly. With the strategic partnership, Shift4 will prioritize Lunchbox as the enterprise solution for its SkyTab POS system.

“We’re excited to partner with Lunchbox as they set the standard for order management and other enterprise restaurant solutions,” said Taylor Lauber, President of Shift4. “By integrating their powerful capabilities into SkyTab POS, we’re able to enhance our product ecosystem to better serve the needs of enterprise restaurants and deliver a unique differentiator to this customer segment. Our investment reflects our confidence in Lunchbox’s vision to continue to transform the restaurant technology landscape.”

With a sharpened focus on AI, automation, and the evolving needs of enterprise brands, Lunchbox is redefining what restaurant technology can achieve. Built by operators, for operators, the platform continues to evolve, with its customers having a direct seat at the table in shaping the roadmap.

About Lunchbox
Lunchbox is the premier restaurant technology solution for enterprise brands, enabling them to scale their digital presence efficiently. With a suite of products specializing in app and web ordering, catering, order aggregation, guest engagement, marketing, and an open API platform, Lunchbox empowers over 5,000+ restaurant locations nationwide, including Firehouse Subs, Torchy’s Tacos, Taco Bueno, and Clean Juice. For more information, visit www.lunchbox.io.

About Shift4
Shift4 (NYSE: FOUR) is boldly redefining commerce by simplifying complex payment ecosystems across the world. As the leader in commerce-enabling technology, Shift4 powers billions of transactions annually for hundreds of thousands of businesses in virtually every industry. For more information, visit shift4.com.

Media Contacts:

Lunchbox

Adriana Desmond

[email protected]

Shift4

Nate Hirshberg


[email protected]

ICR for Shift4

Sara Davis

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunchbox-selects-james-walker-as-ceo-and-announces-new-funding-round-led-by-shift4-302396472.html

SOURCE Lunchbox

SAN JOSE, Calif.
, March 10, 2025 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2025 Annual Meeting of Stockholders (the “Meeting”) on Thursday, March 20, 2025 at 10:00 a.m. Pacific Time in a virtual format.

Following the formal business and voting portion of the Meeting, Anixa Chairman and CEO Dr. Amit Kumar, will deliver an investor presentation and corporate update, followed by a question-and-answer session. All interested parties may attend the Meeting.

All parties may access the Meeting online at www.virtualshareholdermeeting.com/ANIX2025.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa’s therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company’s vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against “retired” proteins that have been found to be expressed in certain forms of cancer. Anixa’s unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa’s current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A – Risk Factors” and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:

Mike Catelani

President, COO & CFO
[email protected]
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-2025-annual-meeting-of-stockholders-to-include-investor-presentation-open-to-all-interested-parties-302396784.html

SOURCE Anixa Biosciences, Inc.

New Solution Supports Growing Demand for AI-Enabled Research & Development Market, Enabling Research Efficiency To Meet Modern Demands

HENDERSON, Nev.
, March 10, 2025 /PRNewswire/ — Research Solutions (NASDAQ: RSSS), a leader in AI-powered scientific research software, announces the launch of an innovative solution that allows customers to purchase legal rights to use scientific journal content within AI applications. For articles from participating publishers, AI use rights can be acquired in the same checkout flow as purchasing articles on the platform and can be purchased retroactively for articles previously purchased.

With this new solution, Research Solutions establishes itself as the definitive bridge between enterprise AI capabilities and scientific content, creating new opportunities for sustainable growth while helping shape the future of research.

“This launch represents a significant milestone in our strategic growth plan, establishing a new licensing framework that addresses critical market friction in the scientific content ecosystem,” said Roy W. Olivier, CEO of Research Solutions. “By building upon our trusted relationships with leading publishers and leveraging our unique market position, we have developed a business model that satisfies both publishers and researchers in the AI era.”

Scientific literature drives billions in R&D investment annually, yet organizations and research teams face significant challenges when attempting to use copyrighted content with AI tools. Research Solutions’ new solution simplifies the process of acquiring the necessary rights to use journal content, ensuring a seamless and legally compliant integration as organizations accelerate their adoption of AI-powered research methodologies.

Developed based on extensive research and discussions with both publishers and customers, the solution is built around detailed business models that work for all stakeholders. By addressing the needs of copyright holders and users alike, it creates a sustainable framework for integrating AI-driven research while protecting intellectual property rights.

“The combination of generative AI and scientific data unlocks unprecedented opportunities for research. Our goal is to facilitate access to relevant literature while ensuring that publishers and authors’ rights are respected including both attribution and remuneration,” said Chris Bendall, VP of Product Strategy with Research Solutions.

The solution delivers multiple strategic advantages, including:

• Sustainable Business Models: Designed in collaboration with publishers and customers to ensure fair value distribution across all stakeholders. Publishers choose which models they wish to participate in.
• Legal Compliance: R&D focused organizations can mitigate risk and potential liability exposure when deploying AI across research operations.
• Increased Efficiency: The solution enables faster and more targeted searching, analysis, and summarization of journal articles to reduce research cycle times.
• Cross-Industry Application: From pharmaceuticals and engineering to business research, all industries can benefit from optimized access to scientific content.

This new solution addresses a pressing need for industry researchers who want to integrate AI into their workflow for searching, analyzing, and summarizing scientific literature.

For more information about AI rights as a publisher or customer please visit: https://www.researchsolutions.com/contact.

About Research Solutions 

Research Solutions (NASDAQ: RSSS) is a vertical SaaS and AI company that simplifies research workflow for academic institutions, life science companies, and research organizations worldwide. As one of the only publisher-independent marketplaces for scientific, technical, and medical (STM) content, the company uniquely combines AI-powered tools—including an intelligent research assistant and full-text search capabilities—with seamless access to both open access and paywalled research. The platform enables organizations to discover, access, manage and analyze scientific literature more efficiently, accelerating the pace of scientific discovery.

LinkedIn
 | Facebook | X 

For more information, visit https://www.researchsolutions.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/research-solutions-launches-clearinghouse-for-ai-rights-to-scientific-literature-302396676.html

SOURCE Research Solutions, Inc.

• 
  Independent study published in Gland Surgery and conducted at Kameda Medical Center in Japan by ProSense® users including Dr. Kizuki Matsumoto and Dr. Eisuke Fukuma
  
• 
  Patients who underwent cryoablation compared to breast-conserving therapy (BCT) reported significantly higher satisfaction (71.0±18.6 vs. 56.3±16.5) in the primary outcome
  
  
  with a mean follow-up of 4.2 and 4.0 years, respectively
  
• 
  Data support continued move toward de-escalation of breast cancer treatment from BCT (lumpectomy) to nonsurgical options including cryoablation
  

CAESAREA, Israel
, March 10, 2025 /PRNewswire/ — IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study titled ‘Post-treatment patient satisfaction in early-stage breast cancer: Comparison of cryoablation versus breast conservation therapy using BREAST-Q’ in the peer reviewed journal Gland Surgery. The study was conducted at the Breast Center, Kameda Medical Center in Kamogawa, Chiba, Japan by the co-authors of the article, Dr. Kizuki Matsumoto, Dr. Yuko Asano, Dr. Hiroki Matsui, and Dr. Eisuke Fukuma. A leading expert and breast surgeon, Dr. Eisuke Fukuma has performed over 600 ProSense® breast cryoablation procedures, has presented on ProSense® and has trained other doctors at medical conferences.

In Japan, the de-escalation of treatment for breast cancer continues, with breast-conserving therapy (“BCT”), typically defined as standard of care breast surgery or lumpectomy, representing approximately 60% of all breast cancer cases, as novel nonsurgical options have emerged.

“In this study we aimed to evaluate and compare patient satisfaction after BCT and cryoablation. Assessing the patient’s health-related quality of life (“HRQOL”) holds significant clinical importance and studies examining long-term satisfaction following cryoablation, particularly in Asian patients, are limited,” stated Dr. Kizuki Matsumoto. “Because of improved survival outcomes, breast cancer is becoming a chronic disease, making the survivor’s quality of life and satisfaction a major focus of treatment. We were pleased with the outcome of the study and believe the use of cryoablation in breast cancer will be more widespread in the future.”

IceCure’s Chief Executive, Eyal Shamir commented, “We are grateful to the team at Kameda Medical Center for initiating this important study which focuses on women’s satisfaction. The data clearly demonstrate that cryoablation resulted in greater quality of life and patient satisfaction than standard of care surgery in this early-stage breast cancer patient population. We believe these results will support our distribution partner, Terumo Corporation, in its application for regulatory approval of ProSense® for breast cancer in Japan.”  

Highlights from the study: 

• A total of 147 Asian female breast cancer patients underwent cryoablation with ProSense® (n=42) or BCT (n=105). Among the 112 patients with stage 0 or 1 disease, 36 met the exclusion criteria and were excluded from the analysis. The remaining 76 (35 from the cryoablation group and 41 from the BCT group) were included in the analysis.
• The study used the BREAST-Q questionnaire to assess patient HRQOL and satisfaction.
• Patients who underwent cryoablation compared to BCT reported significantly higher satisfaction (71.0±18.6 vs. 56.3±16.5) in the primary outcome, with a mean follow-up of 4.2 and 4.0 years, respectively. This satisfaction trend was consistent across all the other measures.
• The authors of the study indicate they believe patient satisfaction is higher with cryoablation of breast cancer as it does not involve excision, leaving breast volume and symmetry unchanged.

About ProSense®

The ProSense® Cryoablation System is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.

ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors.

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company’s flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and China.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that assessing HRQOL holds significant clinical performance; the belief that cryoablation for treating breast cancer will be more widespread in the future; the belief that the data from the Kameda Medical Center study demonstrate that cryoablation resulted in greater quality of life and patient satisfaction than standard of care surgery in the early-stage breast cancer patient population; and the belief that the results from the Kameda Medical Center study will support Terumo Corporation in its application for regulatory approval of ProSense® for breast cancer in Japan. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company’s planned level of revenues and capital expenditures; the Company’s available cash and its ability to obtain additional funding; the Company’s ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company’s ability to maintain its relationships with suppliers, distributors and other partners; the Company’s ability to maintain or protect the validity of its patents and other intellectual property; the Company’s ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023 filed with the SEC on April 3, 2024, and other documents filed with or furnished to the SEC which are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR Contact:
Email: [email protected]
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462

Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/breast-cancer-patients-who-underwent-icecures-prosense-cryoablation-in-japan-reported-significantly-higher-satisfaction-than-patients-who-underwent-standard-of-care-surgery-302396781.html

SOURCE IceCure Medical

The new DxC 500i Analyzer Offers Flexibility and Scalability with

Broad Chemistry and Immunoassay Assay Menu

BREA, Calif.
, March 10, 2025 /PRNewswire/ — Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer, received 510(k) clearance from the U.S. Food and Drug Administration. The DxC 500i combines advanced technology with an intuitive user interface, ensuring that laboratories of all sizes can meet the growing demands of modern healthcare. With throughput of up to 800 clinical chemistry tests per hour and 100 immunoassay tests per hour, this analyzer delivers precise and reliable results critical for timely clinical decision-making.

Healthcare systems around the world and specifically in the United States are strategically adopting networked laboratory operational models for better efficiency and patient access. Approximately 45% of clinical laboratories in the United States — a total of more than 11,000 labs — are associated with an Integrated Delivery Network (IDN).ⁱ IDNs are organizations that provide a coordinated range of healthcare services, including diagnostic testing allowing for better resource management, standardized practices, and enhanced quality of care.

“Innovations like the DxC 500i Clinical Analyzer enable Beckman Coulter to address the needs of networked laboratories with specific solutions for satellite or independent laboratories, as well as core laboratories,” said Kathleen Orland, Chief Portfolio Officer for Beckman Coulter Diagnostics. “Beyond ensuring appropriate throughput levels for a networked lab, Beckman Coulter’s common reagents and consumables across its scalable clinical chemistry and immunoassay portfolio enables common reference ranges, offering IDNs strategic benefits in patient care and inventory management.”

The DxC 500i Clinical Analyzer features FlexMode operations, prioritizing immunoassay and chemistry testing according to each sample’s urgency. The new dynamic sample handler manages repeats and re-runs without operator intervention and pulls in a new sample rack as soon as the previous rack is offloaded, optimizing rapid throughput in a compact footprint. Of equal importance, the DxC 500i Analyzer’s intuitive interface supports even the newest users through proactive task indicators with step-by-step instructions, simplifying staff onboarding and training.

The DxC 500i Clinical Analyzer has been available in countries accepting CE mark since July 2024.

Prior to the DxC 500i Clinical Analyzer introduction, Beckman Coulter unveiled the DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer with onboard guided workflows, more than 120 assays, and standardized reagents for use across healthcare networks. The DxC 500i analyzer incorporates the DxC 500 AU technology within its clinical chemistry capabilities, including its Six Sigma performance.

Not all products are available in all countries. Product availability and regulatory status depends on country registration per applicable regulations.

Follow and connect with Beckman Coulter Diagnostics via LinkedIn, X, and Facebook.

About Beckman Coulter Diagnostics

A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory’s role in improving patient health for more than 90 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time — and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what’s now to what’s next. We seek to accelerate care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and to optimize lab performance services. Headquartered in Brea, Calif., with more than 11,000 global team members, Beckman Coulter Diagnostics is proud to be part of Danaher (NYSE: DHR). Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health.

© 2025 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. The Danaher trademark is a proprietary mark of Danaher Corporation. All other trademarks are the property of their respective owners. 2025-14088

ⁱ Beckman Coulter Diagnostics internal data on file

View original content to download multimedia:https://www.prnewswire.com/news-releases/beckman-coulter-announces-fda-clearance-of-dxc-500i-clinical-analyzer-an-integrated-clinical-chemistry-and-immunoassay-system-302396960.html

SOURCE Beckman Coulter Diagnostics

OKLAHOMA CITY
, March 10, 2025 /PRNewswire/ — SandRidge Energy, Inc. (the “Company” or “SandRidge”) (NYSE: SD) today announced plans to release fourth quarter and full year 2024 operational and financial results after the close of trading on Monday, March 10, 2025.

SandRidge will host a conference call on Tuesday, March 11, 2025 at 1:00 p.m. Central Time to review fourth quarter and full year 2024 financial results and operational highlights. The conference call can be accessed by registering online in advance at https://registrations.events/direct/Q4I2315066 at which time registrants will receive dial-in information as well as a conference ID. At the time of the call, participants will dial in using the participant number and conference ID provided upon registration.

A live audio webcast of the conference call will also be available via the Company’s website, investors.sandridgeenergy.com, under Presentation & Events. The webcast will be archived for replay on the Company’s website for at least 30 days.

About SandRidge Energy, Inc.

SandRidge Energy, Inc. (NYSE: SD) is an independent oil and gas company engaged in the production, development, and acquisition of oil and gas properties. Its primary areas of operations are the Mid-Continent and Western Anadarko regions in Oklahoma, Texas, and Kansas. Further information can be found at sandridgeenergy.com.

Contact Information

Investor Relations
SandRidge Energy, Inc.
1 E. Sheridan Ave. Suite 500
Oklahoma City, OK 73104
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/sandridge-energy-inc-announces-fourth-quarter-and-full-year-2024-operational-and-financial-results-release-date-and-conference-call-information-302396433.html

SOURCE SANDRIDGE ENERGY, INC.

SAN DIEGO
, March 10, 2025 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Semtech Corporation (NASDAQ: SMTC) securities between August 27, 2024 and February 7, 2025, inclusive (the “Class Period”), have until Tuesday, April 22, 2025 to seek appointment as lead plaintiff of the Semtech class action lawsuit. Captioned Kleovoulos v. Semtech Corporation, No. 25-cv-01474 (C.D. Cal.), the Semtech class action lawsuit charges Semtech and certain of Semtech’s top executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Semtech class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-semtech-corporation-class-action-lawsuit-smtc.html
 

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

CASE ALLEGATIONS: Semtech designs, develops, manufactures, and markets analog and mixed-signal semiconductor and advanced algorithms. Semtech’s portfolio includes CopperEdge products, which can be used in active copper cables.

The Semtech class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Semtech’s CopperEdge products did not meet the needs of its server rack customer or end users; (ii) as a result, the CopperEdge products required certain rack architecture changes; (iii) consequently, Semtech’s sales of CopperEdge products would not ramp-up during fiscal 2026; and (iv) as such, sales of CopperEdge products would be lower-than-expected.

The Semtech class action lawsuit further alleges that on February 7, 2025, Semtech revealed that CopperEdge sales would not “ramp-up over the course of fiscal year 2026.” Based on “feedback from a server rack customer” and “discussions with end users of the server rack platform,” Semtech would implement certain “rack architecture changes,” the complaint alleges. As a result, Semtech expected CopperEdge sales to be “lower than the Company’s previously disclosed floor case estimate of $50 million,” according to the Semtech class action lawsuit. On this news, the price of Semtech stock fell approximately 31%, the complaint alleges.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Semtech securities during the Class Period to seek appointment as lead plaintiff in the Semtech class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Semtech class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Semtech class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Semtech class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 

Services may be performed by attorneys in any of our offices. 

Contact:
Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/smtc-investor-deadline-semtech-corporation-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit-302396129.html

SOURCE Robbins Geller Rudman & Dowd LLP

TARGETING APPROXIMATELY 90 OPENINGS IN 2025

DUBLIN, Calif.
, March 10, 2025 /PRNewswire/ — Ross Stores, Inc. opened 16 Ross Dress for Less^® (“Ross”) and three dd’s DISCOUNTS^® stores in 14 different states in March. These new locations are part of the Company’s plans to add approximately 90 new stores, comprised of about 80 Ross and 10 dd’s DISCOUNTS, during fiscal 2025. 

“This Spring, we continued to expand the store base of both Ross and dd’s. Specifically for Ross, we expanded our presence in the newer markets of Connecticut, Minnesota, New Jersey, and New York, while dd’s growth primarily focused on existing markets of California, Georgia, and Texas,” said Richard Lietz, Executive Vice President, Property Development. “We now operate a total of 2,205 Ross Dress for Less and dd’s DISCOUNTS locations across 44 states, the District of Columbia, and Guam. As we look out over the long term, we remain confident that Ross can grow to 2,900 locations and dd’s DISCOUNTS can become a chain of 700 stores given consumers’ ongoing focus on value and convenience.”

About Ross Stores, Inc.


Ross Stores, Inc. is an S&P 500, Fortune 500, and Nasdaq 100 (ROST) company headquartered in Dublin, California, with fiscal 2024 revenues of $21.1 billion. Currently, the Company operates Ross Dress for Less^® (“Ross”), the largest off-price apparel and home fashion chain in the United States with 1,847 locations in 44 states, the District of Columbia, and Guam. Ross offers first-quality, in-season, name brand and designer apparel, accessories, footwear, and home fashions for the entire family at savings of 20% to 60% off department and specialty store regular prices every day. The Company also operates 358 dd’s DISCOUNTS^® in 22 states that feature a more moderately-priced assortment of first-quality, in-season, name brand apparel, accessories, footwear, and home fashions for the entire family at savings of 20% to 70% off moderate department and discount store regular prices every day. Additional information is available at www.rossstores.com.

View original content:https://www.prnewswire.com/news-releases/ross-stores-opens-19-new-locations-302396109.html

SOURCE Ross Stores, Inc.